Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 22;12(11):732. doi: 10.3390/toxins12110732

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of OTA expositions on the Keap1 mRNA expression levels in the kidney. A: Keap1 gene mRNA expressions of the single oral dose (24 h) OTA-treated kidney samples. The highest OTA dose decreased the Keap1 mRNA level (p < 0.01). B: Keap1 gene expression levels of the repeated daily oral dose (72 h) OTA-treated kidney samples. Both applied OTA doses decreased the Keap1 mRNA levels (p < 0.05). C: Keap1 gene expression alterations of the repeated daily oral dose (21 days) OTA-treated kidney samples. The OTA treatment did not influence the Keap1 mRNA level significantly. Abbreviations: MMS: methyl-methanesulfonate-treated group, OTA 1; and OTA 10: 1 and 10 mg/kg bw ochratoxin-A-treated groups in the single oral dose (24 h) and repeated daily oral dose (72 h) experiment; OTA 0.5: 0.5 mg/kg bw ochratoxin-A-treated group in the repeated daily oral dose (21 days) experiment. Mean ± S.D. Data were analyzed by one-way ANOVA and Tukey’s post hoc test.* p < 0.05, ** p < 0.01 vs. vehicle.